Testicular Choriocarcinoma Workup

  • Author: Michael B Williams, MD, MS; Chief Editor: Bradley Fields Schwartz, DO, FACS   more...
 
Updated: Jan 20, 2012
 

Laboratory Studies

Alpha-fetoprotein (AFP) is secreted by yolk sac elements; elevated levels of AFP are consistent with NSGCT. Choriocarcinoma could be a component of such a tumor, but AFP is within the reference range in pure choriocarcinoma. AFP has a serum half-life of between 5 and 7 days.

Human chorionic gonadotropin (hCG) is a glycoprotein with the same alpha unit as thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Therefore, the beta subunit must be assayed. Beta-hCG has a 24- to 36-hour half-life and is secreted by syncytiotrophoblast cells within the tumor. Beta-hCG levels are usually markedly elevated in pure choriocarcinoma. Persistently elevation of beta-hCG levels is defined as continued elevation of the tumor marker above the predicted levels based on serum half-life of 24-36 hours.[6] This can also be applied to AFP, in which levels above that expected for the zero order kinetics of a 5- to 7-day expected half-life represent persistent elevation. From a clinical perspective, persistent tumor marker elevation represents residual disease. As such, more advanced treatment modalities (eg, chemotherapeutic) may be required.

Liver enzyme profile to include lactic acid dehydrogenase (LDH): Elevated levels of LDH may indicate bulky or advanced disease; however, the sensitivity and specificity are limited compared with beta-hCG and AFP. Rising levels after treatment may indicate relapse. Elevation of the remaining liver function tests may correlate with metastatic liver disease.

Placental alkaline phosphatase (PLAP): PLAP is elevated in some patients with seminoma and advanced disease; however, smoking and several other tumors also cause elevations; therefore, this marker not commonly used.

Next

Imaging Studies

Scrotal ultrasonography

Any male with a palpable testicular mass should undergo scrotal ultrasonography. Other indications for ultrasonography may include acute scrotal pain, hydrocele, or other nonspecific scrotal pain, swelling, or mass.

Choriocarcinoma is associated with hemorrhage and necrosis and may appear more cystic, inhomogeneous, and calcified than a seminoma.[7]

Abdominal CT scanning of the abdomen and pelvis with intravenous and oral contrast

In all other forms of testis GCT, CT scanning can be used to most commonly identify metastatic disease to the retroperitoneal lymph nodes, and it understages approximately 15%-20% of patients thought to have stage I.

In patients with pure choriocarcinoma, metastatic disease via hematogenous routes may skip the retroperitoneal lymphatics.

CT scanning of the brain

Choriocarcinoma is associated with brain metastases. In a review of 242 patients with metastatic germ cell testis cancer undergoing treatment with a multi-agent chemotherapy protocol, Vugrin et al (1979) found 38 cases of brain metastases.[8] Among patients with pure embryonal carcinomas, 13% had brain metastases, compared to 83% of patients with pure choriocarcinomas. Furthermore, choriocarcinomas tended to have multiple brain metastatic sites with cerebellar involvement.

In almost all cases, pulmonary metastases preceded or coincided with brain metastases.

Chest radiography/chest CT scanning

Chest CT scan is indicated only for an abnormal finding on chest radiography; however, choriocarcinoma has a high metastatic rate, and CT scanning of the chest is usually indicated.

Bone scan

In an autopsy study by Bredael et al (1982), GCTs had bony metastases at autopsy, including seminoma (56%), mixed choriocarcinoma (35%), teratocarcinoma (30%), and embryonal carcinoma (24%); however, 0 of 6 cases of pure choriocarcinoma metastasized to the bone.[9]

In pure choriocarcinoma, a bone scan can probably be omitted in the absence of bone pain.

Previous
Next

Histologic Findings

Gross findings include a small hemorrhagic nodule with some grayish-white viable tumor at the periphery. Histology shows that choriocarcinoma contains both syncytiotrophoblastic cells and cytotrophoblastic cells in intimate association (see image below).

Testicular choriocarcinoma has multinucleated syncTesticular choriocarcinoma has multinucleated syncytiotrophoblastic cells that drape over smaller cytotrophoblastic cells, which together appear to form a border along a blood-filled villouslike space (upper right). Used with permission from Ernstoff MS, Heaney JA, and Peschel RE, eds. Testicular and Penile Cancer. Malden, Mass: Blackwell Science, Inc; 1998:20.

Syncytiotrophoblastic cells are responsible for beta-HCG production.

Previous
Next

Staging

American Joint Committee on Cancer and the International Union Against Cancer staging systems are described below.

Testicular cancer staging system [10]

  • Primary tumor (T)
    • pTx - Primary tumor cannot be assessed.
    • p0 - No evidence of primary tumor
    • pTis - Intratubular germ cell neoplasia
    • pT1 - Tumor limited to the testis and epididymis, no vascular/lymphatic invasion, may invade the tunica albuginea, no invasion of the tunica vaginalis
    • pT2 - Tumor limited to the testis and epididymis, vascular/lymphatic invasion or tumor extending through the tunica albuginea with involvement of the tunica vaginalis, invades beyond the tunica albuginea or into the epididymis
    • pT3 - Tumor invades the spermatic cord with or without vascular/lymphatic invasion.
    • pT4 - Tumor invades the scrotum with or without vascular/lymphatic invasion, invades the scrotum
  • Regional lymph nodes (N)
    • Clinical
      • Nx - Nodes not assessed
      • N0 - No regional lymph node metastasis
      • N1 - Lymph node mass or multiple lymph node masses less than or equal to 2 cm in greatest dimension
      • N2 - Lymph node mass or multiple lymph node masses greater than 2 cm but less than or equal to 5 cm in greatest dimension
      • N3 - Lymph node mass greater than 5 cm in greatest dimension
    • Pathologic
      • pN0 - No evidence of tumor in lymph nodes
      • pN1 - Lymph node mass less than or equal to 2 cm in greatest dimension, 5 or fewer nodes positive
      • pN2 - Lymph node mass greater than 2 cm but less than 5 cm in greatest dimension, more than 5 nodes positive, evidence of extranodal extension of tumor
      • pN3 - Lymph node mass greater than 5 cm in greatest dimension
  • Distant metastases (M)
    • M0 - No evidence of distant metastases
    • M1a - Nonregional nodal or pulmonary metastases
    • M2b - Nonpulmonary visceral metastases
  • Additional staging systems are well discussed by Prow (1998).[11]

Table 1. Serum Tumor Markers (S) (Open Table in a new window)

SLDHHCG (mIU/mL)AFP (ng/mL)
SxNot assessedNot assessedNot assessed
S0≤ N*andNormalandNormal
S1< 1.5 x Nand< 5000and< 1000
S21.5-10 x Nor5000-50,000or1000-10,000
S3>10 x Nor>50,000or>10,000
*N=upper limit of reference range for the LDH assay

Table 2. Stage Grouping (Open Table in a new window)

Stage groupingTNMS
Stage 0pTisN0M0S0
Stage IT1-T4N0M0Sx
Stage IAT1N0M0S0
Stage IBT2-4N0M0S0
Stage ISAny TN0M0S1-S3
Stage IIAny TAny NM0Sx
Stage IIAAny TN1M0S0-S1
Stage IIBAny TN2M0S0-S1
Stage IICAny TN3M0S0-S1
Stage IIIAny TAny NM1Sx
Stage IIIAAny TAny NM1aS0-S1
Stage IIIBAny TAny NM0-M1aS2
Stage IIICAny TAny NM0-M1aS3
Any TAny NM1bAny S
Previous
 
 
Contributor Information and Disclosures
Author

Michael B Williams, MD, MS  Assistant Professor, Department of Urology, Eastern Virginia Medical School

Michael B Williams, MD, MS is a member of the following medical societies: American Association for Cancer Research, American Association of Clinical Urologists, American Society of Clinical Oncology, American Urological Association, Society of Urologic Oncology, and Texas Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Paul F Schellhammer  MD, Professor of Urology, Eastern Virginia Medical School; Urologist, Urology of Virginia, PC

Paul F Schellhammer is a member of the following medical societies: American Medical Association, American Urological Association, Society of Surgical Oncology, and Society of Urologic Oncology

Disclosure: Nothing to disclose.

John W Davis, MD  Assistant Professor, Department of Urology, University of Texas MD Anderson Cancer Center

John W Davis, MD is a member of the following medical societies: American College of Surgeons and American Urological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Leonard Gabriel Gomella, MD, FACS  The Bernard W Godwin Professor of Prostate Cancer Chairman, Department of Urology, Associate Director of Clinical Affairs, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Leonard Gabriel Gomella, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Urological Association, Sigma Xi, Society for Basic Urologic Research, Society of University Urologists, and Society of Urologic Oncology

Disclosure: GSK Consulting fee Consulting; Astra Zeneca Honoraria Speaking and teaching; Watson Pharmaceuticals Consulting fee Consulting

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Dan Theodorescu, MD, PhD  Paul A Bunn Professor of Cancer Research, Professor of Surgery and Pharmacology, Director, University of Colorado Comprehensive Cancer Center

Dan Theodorescu, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Urological Association, Medical Society of Virginia, Society for Basic Urologic Research, and Society of Urologic Oncology

Disclosure: Key Genomics Ownership interest Co-Founder-50% Stock Ownership; KromaTiD, Inc Stock Options Board membership

J Stuart Wolf Jr, MD, FACS  The David A Bloom Professor of Urology, Director, Division of Endourology and Stone Disease, Department of Urology, University of Michigan Medical School

J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology

Disclosure: Nothing to disclose.

Chief Editor

Bradley Fields Schwartz, DO, FACS  Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists

Disclosure: Nothing to disclose.

References
  1. Mostofi FK, Sesterhenn IA. Anatomy and pathology of testis cancer. In: Comprehensive Textbook of Genitourinary Oncology. Baltimore, Md: Williams and Wilkins; 1996.

  2. Chen X, Xu L, Chen X, Teng X, Zheng S. Testicular choriocarcinoma metastatic to skin and multiple organs. Two case reports and review of literature. J Cutan Pathol. Apr 2010;37(4):486-90. [Medline].

  3. Ramon y Cajal S, Pinango L, Barat A. Metastatic pure choriocarcinoma of the testis in an elderly man. J Urol. Mar 1987;137(3):516-9. [Medline].

  4. Berney DM, Warren AY, Verma M, Kudahetti S, Robson JM, Williams MW, et al. Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. Mod Pathol. Jan 2008;21(1):54-9. [Medline].

  5. Batata MA, Whitmore WF Jr, Chu FC. Cryptorchidism and testicular cancer. J Urol. Sep 1980;124(3):382-7. [Medline].

  6. Klein EA. Tumor markers in testis cancer. Urol Clin North Am. Feb 1993;20(1):67-73. [Medline].

  7. Horstman WG. Scrotal imaging. Urol Clin North Am. Aug 1997;24(3):653-71. [Medline].

  8. Vugrin D, Cvitkovic E, Posner J. Neurological complications of malignant germ cell tumors of testis: biology of brain metastases (I). Cancer. Dec 1979;44(6):2349-53. [Medline].

  9. Bredael JJ, Vugrin D, Whitmore WF Jr. Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer. Aug 1 1982;50(3):548-51. [Medline].

  10. Beahrs O, Henson D, Hutter R. Handbook for staging of cancer. In: The Manual of Staging Cancer. 4th ed. Philadelphia, Pa: JB Lippincott; 1993:195-7.

  11. Prow DM. Germ cell tumors: staging, prognosis, and outcome. Semin Urol Oncol. May 1998;16(2):82-93. [Medline].

  12. Logothetis CJSamuels MLSelig DEOgden SDexeus FSwanson DJohnson Dvon Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. American Journal of Medicine. 2/1986;81:219-28. [Medline].

  13. Tatokoro M, Kawakami S, Sakura M, Kobayashi T, Kihara K, Akamatsu H. Successful management of life-threatening choriocarcinoma syndrome with rupture of pulmonary metastatic foci causing hemorrhagic shock. Int J Urol. Mar 2008;15(3):263-4. [Medline].

  14. Bodiwala D, Summerton DJ, Terry TR. Testicular prostheses: development and modern usage. Ann Royal Coll Surg Engl. 2007;89:349-53. [Medline]. [Full Text].

  15. Mead GM. Chemotherapeutic Management of Metastatic Germ Cell Testis Cancer. Risk-Adapted Therapy/Poor Risk Patients. In: Vogelzang et al, eds. Comprehensive Textbook of Genitourinary Oncology. 2nd ed. Philadelphia, Pa: Lippincott Williams & Williams; 2000:1024-31.

  16. Requena L, Sanchez M, Aguilar A. Choriocarcinoma of the testis metastatic to the skin. J Dermatol Surg Oncol. May 1991;17(5):466-70. [Medline].

  17. Saxman SB, Loehrer PJ. Chemotherapeutic Management of Metastatic Germ Cell Testicular Cancer. Overview of Initial Therapy for Metastatic Seminoma and Nonseminoma. In: Vogelzang et al, eds. Comprehensive Textbook of Genitourinary Oncology. 2000. 2nd ed. Philadelphia, Pa: Lippincott Williams & Williams; 1010-7.

  18. Batata MA, Chu FC, Hilaris BS. Therapy and prognosis of testicular carcinomas in relation to TNM classification. Int J Radiat Oncol Biol Phys. Aug 1982;8(8):1287-93. [Medline].

  19. Lepidini G, Biancari F, D'Andrea V. Severe thrombosis after chemotherapy for metastatic choriocarcinoma of the testis maintaining complete remission for a long period. Scand J Urol Nephrol. Apr 1997;31(2):221-2. [Medline].

  20. Bosl GJ, Geller N, Cirrincione C. Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis. Cancer. Jun 1 1983;51(11):2121-5. [Medline].

  21. Azzopardi JG, Mostofi FK, Theiss EA. Lesions of the testes observed in certain patients with widespread choriocarcinoma and related tumors. Am J Pathol. 1961;38:207-225.

  22. Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. 5th ed. New York, NY: Lippincott-Raven; 1997.

  23. Kodama M, Murakami M, Kodama T. Chronological transition of the age-adjusted incidence rates (AAIRs) of 20 major neoplasias from early 1960s to mid-1980s. Anticancer Res. Jan-Feb 1999;19(1B):779-87. [Medline].

  24. Looijenga LH, Oosterhuis JW. Pathogenesis of testicular germ cell tumours. Rev Reprod. May 1999;4(2):90-100. [Medline].

  25. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ. 1992;45-173. [Medline].

  26. Richie JP. Neoplasms of the Testis. In: Campbell's Urology. 7th ed. Philadelphia, Pa: WB Saunders Co; 1998.

  27. Ro JY, Dexeus FH, el-Naggar A. Testicular germ cell tumors. Clinically relevant pathologic findings. Pathol Annu. 1991;26 Pt 2:59-87. [Medline].

  28. Swerdlow AJ. Epidemiology of testicular cancer. In: Principles and Practice of Genitourinary Oncology. Philadelphia, Pa: Lippincott-Raven Publishers; 1997.

  29. Ulbright TM. Germ cell neoplasms of the testis. Am J Surg Pathol. Nov 1993;17(11):1075-91. [Medline].

Previous
Next
 
Testicular choriocarcinoma has multinucleated syncytiotrophoblastic cells that drape over smaller cytotrophoblastic cells, which together appear to form a border along a blood-filled villouslike space (upper right). Used with permission from Ernstoff MS, Heaney JA, and Peschel RE, eds. Testicular and Penile Cancer. Malden, Mass: Blackwell Science, Inc; 1998:20.
Table 1. Serum Tumor Markers (S)
SLDHHCG (mIU/mL)AFP (ng/mL)
SxNot assessedNot assessedNot assessed
S0≤ N*andNormalandNormal
S1< 1.5 x Nand< 5000and< 1000
S21.5-10 x Nor5000-50,000or1000-10,000
S3>10 x Nor>50,000or>10,000
*N=upper limit of reference range for the LDH assay
Table 2. Stage Grouping
Stage groupingTNMS
Stage 0pTisN0M0S0
Stage IT1-T4N0M0Sx
Stage IAT1N0M0S0
Stage IBT2-4N0M0S0
Stage ISAny TN0M0S1-S3
Stage IIAny TAny NM0Sx
Stage IIAAny TN1M0S0-S1
Stage IIBAny TN2M0S0-S1
Stage IICAny TN3M0S0-S1
Stage IIIAny TAny NM1Sx
Stage IIIAAny TAny NM1aS0-S1
Stage IIIBAny TAny NM0-M1aS2
Stage IIICAny TAny NM0-M1aS3
Any TAny NM1bAny S
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.